• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • Insight
11 min read 23rd March 2022

NICE’s severity modifier: a step in the right direction, but still a long way to go

Priority setting in health is an important, and sometimes controversial topic. In practice, many health technology assessment agencies give a higher weighting to treatments with ‘desirable’ characteristics. For example, treatments for severe and/or rare diseases. In this blog, we review…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

Priority setting in health is an important, and sometimes controversial topic. In practice, many health technology assessment agencies give a higher weighting to treatments with ‘desirable’ characteristics. For example, treatments for severe and/or rare diseases. In this blog, we review changes to NICE’s manual to include a new ‘severity modifier’.

This blog post is the fifth in a series on the new National Institute for Health and Care Excellence (NICE) health technology evaluation manual. Each post provides a critical discussion on a particular topic, including the expected implications of the changes (or lack thereof) in the manual; what is still missing; and what further research is needed.

It is broadly accepted that the severity of a disease is an important consideration in health technology assessment (HTA). In many countries, HTA agencies use disease severity as a decision-making ‘modifier’ (Zhang and Garau, 2020). This is where flexibility is provided if the medicine being appraised is for a severe disease, which in some cases means that a higher cost-effectiveness threshold (or quality-adjusted life year [QALY] weighting) may be formally applied.

NICE essentially first introduced a ‘severity modifier’ – the ‘end-of-life (EOL) criteria’ – in 2009. The EOL criteria were criticised for being too narrow and not considering improvements in quality of life. Furthermore, UK-based societal preference studies typically did not find evidence in support of an end-of-life premium (Shah et al., 2018).

NICE’s new health technology evaluation manual replaces the EOL criteria with a new, broader severity modifier. This blog outlines the new modifier and discusses the need for further related research.

What is NICE’s new severity modifier?

NICE’s new severity modifier considers two different – but related – measures of disease severity: absolute QALY shortfall (AS) and proportional QALY shortfall (PS).

AS represents the number of future QALYs that are lost by people living with the disease. Younger individuals have a greater number of potential future QALYs to lose on average and therefore severe chronic diseases that affect younger patient populations may have higher AS scores on average compared to severe acute diseases that affect older populations.

The opposite is true for PS. PS represents the proportion of future QALYs that are lost by people living with the disease. Elderly patient populations that are nearer to the end of their lives have relatively fewer potential QALYs left on average and therefore are more likely to lose a higher proportion of their remaining QALYs as a result of a severe disease, leading to higher PS scores on average.

Given the above, the two measures can be considered as complementary and, when used together, they provide a relatively broad definition of severity. Indeed, NICE’s new severity modifier considers both measures. If the AS or PS scores are high enough, a QALY weight is applied, effectively increasing the cost-effectiveness threshold. The table below contains the three categories for the QALY weights. If both scores indicate that a QALY weight should be applied, and the weights differ, the higher weight is applied.

QALY weight Proportional QALY shortfall Absolute QALY shortfall
1 Less than 0.85 Less than 12
x1.2 0.85 to 0.95 12 to 18
x1.7 At least 0.95 At least 18

It is worth noting that NICE’s specific guidance on the calculation of AS and PS scores has some implications. Firstly, they recommend that the scores take into consideration the current standard of care, which effectively means that the severity modifier also accounts for aspects of ‘unmet need’ (Zhang et al., 2021). Furthermore, they recommend that the scores are calculated using discounting. Therefore, technically the AS (PS) scores represent the number (proportion) of discounted future QALYs that are lost by people living with the disease and receiving the standard of care.

How was the modifier designed and what future research is required?

NICE’s new severity modifier is arguably an improvement over the EOL criteria that it replaces because it defines severity more broadly. However, one of the main pieces of criticism that the EOL criteria (fairly) received also applies here: there is little evidence indicating that the modifier aligns with societal preferences.

To come up with the categories in the earlier table, NICE looked at a selection of past appraisals, and estimated the average QALY weight that was applied previously via the EOL criteria. They then estimated AS and PS scores for the same set of appraisals and identified a combination of cut-offs that would have resulted in an equivalent average QALY weight. They referred to this as an “opportunity cost neutral” approach.

Whilst this approach may make sense to arrive at a starting point, it is notable that the severity categories that are eligible for a QALY weight are higher than severity categories applied elsewhere in the world. In the Netherlands PS is used to define severity, and the highest severity category is for PS scores that exceed 0.70 (compared to ≥0.95 with NICE’s modifier). Furthermore, in Norway, AS is used to define severity, and the highest severity category is for undiscounted AS scores that exceed 20 (compared to discounted AS scores of ≥18). Therefore, NICE’s severity modifier may only be relevant in a small number of exceptional cases.

The appropriateness of these severity categories will be better understood when a societal preference study has been conducted – and thankfully NICE have acknowledged the need for such a study and further refinement of the modifier. However, the scope of such a study is unclear. Should societal preferences be used solely to determine the appropriate categories, or extend to the number of severity categories, or the magnitude of the adjustments?

There are also numerous technical challenges associated with conducting a societal preference study in this context. AS and PS are related measures, and it may prove difficult to include both within the same preference elicitation exercise. There is also the issue of using discounting in QALY shortfall calculations. The preference elicitation exercise will most likely consider undiscounted QALY shortfall scores to enable respondents to understand the task – but how will this be translated into categories based on discounted scores? And how will it be determined that the general population actually agree with the value judgements implied by discounting QALY shortfall scores?

NICE’s severity modifier is a step in the right direction, but there is still a long way to go.

OHE look forward to contributing to further research and debate in this area in the near future. Our next masterclass will explore the consideration of severity in value assessment – we hope to see you there!

Citation

Shah, K. K., Tsuchiya, A., & Wailoo, A. J. (2018). Valuing health at the end of life: A review of stated preference studies in the social sciences literature. Social Science & Medicine, 204, 39–50.

Zhang, K., and Garau, M. 2020. International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making. OHE Consulting Report.

Zhang, K., Kumar, G., & Skedgel, C. 2021. Towards a New Understanding of Unmet Medical Need. Applied Health Economics and Health Policy, 19(6), 785–788.

Related Research

Zhang, K., Garau, M. (2020) International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making. Consulting Report.

Related blogs

A series on the new National Institute for Health and Care Excellence (NICE) health technology evaluation manual

  • New NICE Manual for Health Technology Evaluations: A Critical Discussion on the Most Relevant Changes (or Lack Thereof)
  • To Hell with the 3L! NICE’s Missed Opportunity to Upgrade Health Outcome Measurement
  • Including Carer Quality of Life in Health Technology Evaluation: Are We There Yet?
  • The NICE Health Technology Evaluation Manual: A Fresh Perspective Needed?
  • Let’s talk about (health) inequalities
  • Health Technology Assessment…
  • Value, Affordability, and…
  • NICE

Related Insights

Blog 4
  • Insight
  • October 2022

The Economics of Antibiotics – Part 4: What Does the Antibiotics Market of the Future Look Like?

Read more
Slide3
  • Insight
  • October 2022

The Economics of Antibiotics – Part 3: Creating a Healthy Global Market for New Antibiotics

Read more
Sleepio_Adobe_montblanca-e1673970227875
  • Insight
  • May 2022

Sleepio: Lessons from the Frontier of Digital Therapeutics

Read more
3D Isometric Flat Vector Conceptual Illustration of Health Equit
  • Insight
  • April 2022

Let’s talk about (health) inequalities

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!